A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
NCT02304315
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis B Infection
Interventions
BIOLOGICAL:
GC1102 50,000 IU
BIOLOGICAL:
GC1102 80,000 IU
Sponsor
Green Cross Corporation